投中一颗抗癌药丸，南通包工头狂揽110亿

Core Insights - The article highlights the remarkable transformation of Du Jinhao from a construction contractor to a pharmaceutical tycoon, leading the innovative drug company Ailis, which achieved significant revenue growth and profitability in a short period [2][4]. Financial Performance - Ailis generated revenue of 23.7 billion yuan in the first half of the year, with a net profit of 10.5 billion yuan, marking a year-on-year increase of over 60% [7][8]. - From 2021 to 2024, Ailis's revenue surged from 530 million yuan to 3.558 billion yuan, nearly a sevenfold increase, and the company turned a profit of 1.43 billion yuan in 2023 [5][7]. - The company's gross margin has consistently remained above 95%, reaching 98.94% in 2021 [13]. Product Development - Ailis has three commercialized products, with the core product being the small molecule targeted drug Fumetnib, which was approved in 2021 and has contributed over 90% of the company's revenue [8][10]. - The market demand for EGFR-TKI drugs in China is projected to reach 30 billion yuan by 2030, with Fumetnib being a third-generation EGFR-TKI inhibitor known for its clinical efficacy and lower adverse reactions [10]. Market Position and Strategy - Ailis's stock price has increased over 200% this year, reflecting strong market interest driven by its solid fundamentals [5]. - The company is actively seeking new targets for expansion, focusing on the oncology sector [4]. Leadership and Ownership - Du Jinhao and his wife hold over 37% of Ailis's shares, with their combined wealth reaching 11 billion yuan, placing them on the Hurun Global Rich List [14][15]. - The company has a robust cash position, with Du Jinhao holding 1 billion yuan in cash and the company’s total cash exceeding 4.2 billion yuan [15]. Employee Compensation - Employee salaries have significantly increased, with average annual salaries rising from 230,000 yuan in 2020 to 480,000 yuan in 2024 [15][17].